Literature DB >> 17175228

Role of CXCR3 and CCR5 in allograft rejection.

G T Schnickel1, G R Hsieh, C Garcia, A Shefizadeh, M C Fishbein, A Ardehali.   

Abstract

UNLABELLED: Chemokines are known to participate in allograft rejection by mediating leukocyte trafficking. Despite redundancy in chemokine family, several chemokine-chemokine receptor interactions have proven critical in alloimmune responses. We sought to determine the effect of combined blockade of CXCR3 and CCR5, two critical chemokine receptors, in acute rejection.
METHODS: Heterotopic heart transplantation was performed using BALB/c to B6/129 mice deficient in CCR5. Following transplantation these mice were treated with goat anti-CXCR3 serum every other day. In the control group, BALB/c hearts were transplanted in wild type B6/129 recipients and treated with goat serum alone. No immunosuppression was given to either group. Recipient mice were then assessed daily for allograft function by abdominal palpation, and graft survival was confirmed by laparotomy.
RESULTS: The donor hearts in the control group were rejected at 6 +/- 1 days posttransplantation. Combined blockade of CXCR3 and CCR5 prolonged allograft survival versus control; all allografts survived to 24 days. In addition, there was a decrease in graft infiltrating CD4 and CD8 lymphocytes in the experimental group at 24 days.
CONCLUSION: Combined CXCR3 and CCR5 blockade is effective in prolonging allograft survival in a fully MHC mismatched murine model. Combined chemokine blockade holds promise in control of acute rejection in organ transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17175228     DOI: 10.1016/j.transproceed.2006.10.164

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection.

Authors:  Guanfang Shi; David J Field; Kyung-ae Ko; Sara Ture; Kalyan Srivastava; Scott Levy; M Anna Kowalska; Mortimer Poncz; Deborah J Fowell; Craig N Morrell
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

2.  Chronic inflammatory lesions of the placenta are associated with an up-regulation of amniotic fluid CXCR3: A marker of allograft rejection.

Authors:  Eli Maymon; Roberto Romero; Gaurav Bhatti; Piya Chaemsaithong; Nardhy Gomez-Lopez; Bogdan Panaitescu; Noppadol Chaiyasit; Percy Pacora; Zhong Dong; Sonia S Hassan; Offer Erez
Journal:  J Perinat Med       Date:  2018-02-23       Impact factor: 1.901

3.  Peripherally circulating CD4⁺ FOXP3⁺ CXCR3⁺ T regulatory cells correlate with renal allograft function.

Authors:  A Hoerning; S Köhler; C Jun; B Tebbe; J Fu; J Menke; B Wilde; S Dolff; T Feldkamp; D M Briscoe; A Kribben; P F Hoyer; O Witzke
Journal:  Scand J Immunol       Date:  2012-09       Impact factor: 3.487

4.  Antibody-suppressor CD8+ T Cells Require CXCR5.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Steven M Elzein; Christina L Avila; Robert T Warren; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2019-09       Impact factor: 4.939

5.  Characterization of effector T cells in dry eye disease.

Authors:  Jaafar El Annan; Sunil K Chauhan; Tatiana Ecoiffier; Qiang Zhang; Daniel R Saban; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-01       Impact factor: 4.799

6.  Metabolic profiling of ligands for the chemokine receptor CXCR3 by liquid chromatography-mass spectrometry coupled to bioaffinity assessment.

Authors:  Marija Mladic; Danny J Scholten; Maikel Wijtmans; David Falck; Rob Leurs; Wilfried M A Niessen; Martine J Smit; Jeroen Kool
Journal:  Anal Bioanal Chem       Date:  2015-07-12       Impact factor: 4.142

7.  Circulating Donor-Specific Anti-HLA Antibodies Associate With Immune Activation Independent of Kidney Transplant Histopathological Findings.

Authors:  Elisabet Van Loon; Baptiste Lamarthée; Thomas Barba; Sandra Claes; Maarten Coemans; Henriette de Loor; Marie-Paule Emonds; Priyanka Koshy; Dirk Kuypers; Paul Proost; Aleksandar Senev; Ben Sprangers; Claire Tinel; Olivier Thaunat; Amaryllis H Van Craenenbroeck; Dominique Schols; Maarten Naesens
Journal:  Front Immunol       Date:  2022-02-23       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.